Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,419
archived clinical trials in
Pulmonary

Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated:  3/20/2013
1199.15.10112 Boehringer Ingelheim Investigational Site
mi
from
Vancouver, WA
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated: 3/20/2013
1199.15.10112 Boehringer Ingelheim Investigational Site
mi
from
Vancouver, WA
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated:  3/20/2013
1245.25.10182 Boehringer Ingelheim Investigational Site
mi
from
Morgantown, WV
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated: 3/20/2013
1245.25.10182 Boehringer Ingelheim Investigational Site
mi
from
Morgantown, WV
Click here to add this to my saved trials
Study of Default Options in Advance Directives
Default Options in Advance Directives for Veterans With Serious Illnesses: A Randomized Clinical Trial
Status: Enrolling
Updated:  3/21/2013
Philadelphia Veterans Affairs Medical Center
mi
from
Philadelphia, PA
Study of Default Options in Advance Directives
Default Options in Advance Directives for Veterans With Serious Illnesses: A Randomized Clinical Trial
Status: Enrolling
Updated: 3/21/2013
Philadelphia Veterans Affairs Medical Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Effects of Positive Airway Pressure (PAP) in Children With Obstructive Sleep Apnea (OSA)
Neurobehavioral Effects of Positive Airway Pressure (PAP) Therapy in Children With Obstructive Sleep Apnea
Status: Enrolling
Updated:  4/2/2013
Sleep Diagnostics Center at Tucson Medical Center
mi
from
Tucson, AZ
Effects of Positive Airway Pressure (PAP) in Children With Obstructive Sleep Apnea (OSA)
Neurobehavioral Effects of Positive Airway Pressure (PAP) Therapy in Children With Obstructive Sleep Apnea
Status: Enrolling
Updated: 4/2/2013
Sleep Diagnostics Center at Tucson Medical Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Study of Erythromycin in GER-Associated Apnea of the Newborn
Study of Erythromycin in GER-Associated Apnea of the Newborn
Status: Enrolling
Updated:  4/2/2013
University of Virginia Children's Hospital
mi
from
Charlottesville, VA
Study of Erythromycin in GER-Associated Apnea of the Newborn
Study of Erythromycin in GER-Associated Apnea of the Newborn
Status: Enrolling
Updated: 4/2/2013
University of Virginia Children's Hospital
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Web-based Delivery of Effective Treatment for Growth in Cystic Fibrosis
Web-based Delivery of Effective Treatment for Growth in Cystic Fibrosis
Status: Enrolling
Updated:  4/8/2013
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Web-based Delivery of Effective Treatment for Growth in Cystic Fibrosis
Web-based Delivery of Effective Treatment for Growth in Cystic Fibrosis
Status: Enrolling
Updated: 4/8/2013
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Assessment of PPG & PAT to Detect Upper Airway Obstruction in Patients With Obstructive Sleep Apnea
Assessment of a New Photoplethysmographic (PPG) Method and a Pulse Arrival Time Method to Detect Upper Airway Obstruction in Patients With Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) in a Sleep Laboratory
Status: Enrolling
Updated:  4/9/2013
Palomar Hospital
mi
from
Escondido, CA
Assessment of PPG & PAT to Detect Upper Airway Obstruction in Patients With Obstructive Sleep Apnea
Assessment of a New Photoplethysmographic (PPG) Method and a Pulse Arrival Time Method to Detect Upper Airway Obstruction in Patients With Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) in a Sleep Laboratory
Status: Enrolling
Updated: 4/9/2013
Palomar Hospital
mi
from
Escondido, CA
Click here to add this to my saved trials
A Phase 1 Study to Characterize the Effect of GS-5737 Enhancement of Mucociliary Clearance (MCC) in Healthy Subjects
A Phase 1, Randomized, Double-Blind, Cross-Over, Vehicle-Controlled, Single-Dose Study To Characterize The Effect of GS-5737 Enhancement of Mucociliary Clearance (MCC) In Healthy Subjects
Status: Enrolling
Updated:  4/10/2013
Clinical Research Facility
mi
from
Charlotte, NC
A Phase 1 Study to Characterize the Effect of GS-5737 Enhancement of Mucociliary Clearance (MCC) in Healthy Subjects
A Phase 1, Randomized, Double-Blind, Cross-Over, Vehicle-Controlled, Single-Dose Study To Characterize The Effect of GS-5737 Enhancement of Mucociliary Clearance (MCC) In Healthy Subjects
Status: Enrolling
Updated: 4/10/2013
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
Comparison of Supportive Therapies for Symptom Relief From Pediatric Upper Respiratory Infections (URIs)
Comparison of Supportive Therapies for Symptom Relief From Pediatric Upper Respiratory Infections (URIs)
Status: Enrolling
Updated:  5/6/2013
University of California - San Francisco
mi
from
San Francisco, CA
Comparison of Supportive Therapies for Symptom Relief From Pediatric Upper Respiratory Infections (URIs)
Comparison of Supportive Therapies for Symptom Relief From Pediatric Upper Respiratory Infections (URIs)
Status: Enrolling
Updated: 5/6/2013
University of California - San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Exercise-Induced Bronchospasm in Cystic Fibrosis
Exercise-Induced Bronchospasm in Cystic Fibrosis
Status: Enrolling
Updated:  5/13/2013
Ohio State University
mi
from
Columbus, OH
Exercise-Induced Bronchospasm in Cystic Fibrosis
Exercise-Induced Bronchospasm in Cystic Fibrosis
Status: Enrolling
Updated: 5/13/2013
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Utility of Syringe Based Suction Versus Channel Suction in Bronchoalveolar Lavage
Utility of Syringe Based Suction Versus Channel Suction in Bronchoalveolar Lavage
Status: Enrolling
Updated:  5/14/2013
OUHSC
mi
from
Oklahoma City, OK
Utility of Syringe Based Suction Versus Channel Suction in Bronchoalveolar Lavage
Utility of Syringe Based Suction Versus Channel Suction in Bronchoalveolar Lavage
Status: Enrolling
Updated: 5/14/2013
OUHSC
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated:  5/15/2013
1222.52.02090 Boehringer Ingelheim Investigational Site
mi
from
Anniston, AL
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated: 5/15/2013
1222.52.02090 Boehringer Ingelheim Investigational Site
mi
from
Anniston, AL
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated:  5/15/2013
Boehringer Ingelheim Investigational Site
mi
from
Birmingham, AL
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated: 5/15/2013
Boehringer Ingelheim Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated:  5/15/2013
205.452.01244 Boehringer Ingelheim Investigational Site
mi
from
Mobile, AL
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated: 5/15/2013
205.452.01244 Boehringer Ingelheim Investigational Site
mi
from
Mobile, AL
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated:  5/15/2013
205.452.01041 Boehringer Ingelheim Investigational Site
mi
from
Montgomery, AL
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated: 5/15/2013
205.452.01041 Boehringer Ingelheim Investigational Site
mi
from
Montgomery, AL
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated:  5/15/2013
205.452.01070 Boehringer Ingelheim Investigational Site
mi
from
Anchorage, AK
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated: 5/15/2013
205.452.01070 Boehringer Ingelheim Investigational Site
mi
from
Anchorage, AK
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated:  5/15/2013
205.452.01218 Boehringer Ingelheim Investigational Site
mi
from
Chandler, AZ
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated: 5/15/2013
205.452.01218 Boehringer Ingelheim Investigational Site
mi
from
Chandler, AZ
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated:  5/15/2013
1301.1.5727 Boehringer Ingelheim Investigational Site
mi
from
Glendale, AZ
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated: 5/15/2013
1301.1.5727 Boehringer Ingelheim Investigational Site
mi
from
Glendale, AZ
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated:  5/15/2013
1245.25.10175 Boehringer Ingelheim Investigational Site
mi
from
Peoria, AZ
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated: 5/15/2013
1245.25.10175 Boehringer Ingelheim Investigational Site
mi
from
Peoria, AZ
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated:  5/15/2013
205.452.01283 Boehringer Ingelheim Investigational Site
mi
from
Phoenix, AZ
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated: 5/15/2013
205.452.01283 Boehringer Ingelheim Investigational Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated:  5/15/2013
1222.29.11006 Boehringer Ingelheim Investigational Site
mi
from
Huntington Beach, CA
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated: 5/15/2013
1222.29.11006 Boehringer Ingelheim Investigational Site
mi
from
Huntington Beach, CA
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated:  5/15/2013
1268.17.01024 Boehringer Ingelheim Investigational Site
mi
from
San Jose, CA
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated: 5/15/2013
1268.17.01024 Boehringer Ingelheim Investigational Site
mi
from
San Jose, CA
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated:  5/15/2013
205.440.1002 Boehringer Ingelheim Investigational Site
mi
from
Torrance, CA
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated: 5/15/2013
205.440.1002 Boehringer Ingelheim Investigational Site
mi
from
Torrance, CA
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated:  5/15/2013
1237.5.01015 Boehringer Ingelheim Investigational Site
mi
from
Boulder, CO
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated: 5/15/2013
1237.5.01015 Boehringer Ingelheim Investigational Site
mi
from
Boulder, CO
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated:  5/15/2013
205.452.01018 Boehringer Ingelheim Investigational Site
mi
from
Fort Collins, CO
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated: 5/15/2013
205.452.01018 Boehringer Ingelheim Investigational Site
mi
from
Fort Collins, CO
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated:  5/15/2013
205.440.1018 Boehringer Ingelheim Investigational Site
mi
from
Hartford, CT
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated: 5/15/2013
205.440.1018 Boehringer Ingelheim Investigational Site
mi
from
Hartford, CT
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated:  5/15/2013
205.452.01072 Boehringer Ingelheim Investigational Site
mi
from
Norwalk, CT
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated: 5/15/2013
205.452.01072 Boehringer Ingelheim Investigational Site
mi
from
Norwalk, CT
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated:  5/15/2013
205.452.01109 Boehringer Ingelheim Investigational Site
mi
from
Waterbury, CT
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated: 5/15/2013
205.452.01109 Boehringer Ingelheim Investigational Site
mi
from
Waterbury, CT
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated:  5/15/2013
205.452.01011 Boehringer Ingelheim Investigational Site
mi
from
Clearwater, FL
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated: 5/15/2013
205.452.01011 Boehringer Ingelheim Investigational Site
mi
from
Clearwater, FL
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated:  5/15/2013
1245.23.10042 Boehringer Ingelheim Investigational Site
mi
from
Fort Lauderdale, FL
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated: 5/15/2013
1245.23.10042 Boehringer Ingelheim Investigational Site
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated:  5/15/2013
Boehringer Ingelheim Investigational Site
mi
from
Orlando, FL
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated: 5/15/2013
Boehringer Ingelheim Investigational Site
mi
from
Orlando, FL
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated:  5/15/2013
1222.52.02016 Boehringer Ingelheim Investigational Site
mi
from
Ponte Verda, FL
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated: 5/15/2013
1222.52.02016 Boehringer Ingelheim Investigational Site
mi
from
Ponte Verda, FL
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated:  5/15/2013
1222.52.02084 Boehringer Ingelheim Investigational Site
mi
from
St. Petersberg, FL
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated: 5/15/2013
1222.52.02084 Boehringer Ingelheim Investigational Site
mi
from
St. Petersberg, FL
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated:  5/15/2013
1199.15.10027 Boehringer Ingelheim Investigational Site
mi
from
Tampa, FL
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated: 5/15/2013
1199.15.10027 Boehringer Ingelheim Investigational Site
mi
from
Tampa, FL
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated:  5/15/2013
1245.28.10033 Boehringer Ingelheim Investigational Site
mi
from
Blue Ridge, GA
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated: 5/15/2013
1245.28.10033 Boehringer Ingelheim Investigational Site
mi
from
Blue Ridge, GA
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated:  5/15/2013
1275.1.01111 Boehringer Ingelheim Investigational Site
mi
from
Duluth, GA
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated: 5/15/2013
1275.1.01111 Boehringer Ingelheim Investigational Site
mi
from
Duluth, GA
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated:  5/15/2013
1222.52.02077 Boehringer Ingelheim Investigational Site
mi
from
Gainsville, GA
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated: 5/15/2013
1222.52.02077 Boehringer Ingelheim Investigational Site
mi
from
Gainsville, GA
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated:  5/15/2013
1222.52.02040 Boehringer Ingelheim Investigational Site
mi
from
Rincon, GA
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated: 5/15/2013
1222.52.02040 Boehringer Ingelheim Investigational Site
mi
from
Rincon, GA
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated:  5/15/2013
205.452.01166 Boehringer Ingelheim Investigational Site
mi
from
Hayden Lake, ID
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated: 5/15/2013
205.452.01166 Boehringer Ingelheim Investigational Site
mi
from
Hayden Lake, ID
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated:  5/15/2013
1237.5.01031 Boehringer Ingelheim Investigational Site
mi
from
O'Fallon, IL
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated: 5/15/2013
1237.5.01031 Boehringer Ingelheim Investigational Site
mi
from
O'Fallon, IL
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated:  5/15/2013
205.440.1017 Boehringer Ingelheim Investigational Site
mi
from
Muncie, IN
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated: 5/15/2013
205.440.1017 Boehringer Ingelheim Investigational Site
mi
from
Muncie, IN
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated:  5/15/2013
1222.52.02008 Boehringer Ingelheim Investigational Site
mi
from
Fort Mitchell, KY
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated: 5/15/2013
1222.52.02008 Boehringer Ingelheim Investigational Site
mi
from
Fort Mitchell, KY
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated:  5/15/2013
1199.14.1172 Boehringer Ingelheim Investigational Site
mi
from
Louisville, KY
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated: 5/15/2013
1199.14.1172 Boehringer Ingelheim Investigational Site
mi
from
Louisville, KY
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated:  5/15/2013
1200.75.10019 Boehringer Ingelheim Investigational Site
mi
from
New Orleans, LA
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated: 5/15/2013
1200.75.10019 Boehringer Ingelheim Investigational Site
mi
from
New Orleans, LA
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated:  5/15/2013
Boehringer Ingelheim Investigational Site
mi
from
Baltimore, MD
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated: 5/15/2013
Boehringer Ingelheim Investigational Site
mi
from
Baltimore, MD
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated:  5/15/2013
205.452.01336 Boehringer Ingelheim Investigational Site
mi
from
Hollywood, MD
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated: 5/15/2013
205.452.01336 Boehringer Ingelheim Investigational Site
mi
from
Hollywood, MD
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated:  5/15/2013
1222.52.02015 Boehringer Ingelheim Investigational Site
mi
from
Townson, MD
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated: 5/15/2013
1222.52.02015 Boehringer Ingelheim Investigational Site
mi
from
Townson, MD
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated:  5/15/2013
1222.29.11004 Boehringer Ingelheim Investigational Site
mi
from
North Dartmouth, MA
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated: 5/15/2013
1222.29.11004 Boehringer Ingelheim Investigational Site
mi
from
North Dartmouth, MA
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated:  5/15/2013
205.452.01365 Boehringer Ingelheim Investigational Site
mi
from
Chelsea, MI
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated: 5/15/2013
205.452.01365 Boehringer Ingelheim Investigational Site
mi
from
Chelsea, MI
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated:  5/15/2013
205.452.01080 Boehringer Ingelheim Investigational Site
mi
from
Kalamazoo, MI
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]
Status: Enrolling
Updated: 5/15/2013
205.452.01080 Boehringer Ingelheim Investigational Site
mi
from
Kalamazoo, MI
Click here to add this to my saved trials